Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma

por Andrew J. Brenner, John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, Eudocia Quant Lee
Publicado 2021